Looking back at old interviews ( could tell the story ) ( PART 1 )
This Company or Blog sight Interviewed Gary Rabin
The Knoepfler Lab Stem Cell Blog
I HAVE POSTED ONE OF THE QUESTIONS THAT I LIKED AFTER READING THIS ARTICLE. YES THE ARTICLE WAS WRITTEN MAY 1ST 2013, BUT NOW WITH THE NEW NEWS THAT WE HAVE, ( WOW ) WHO IS GOING TO BE CALLING ON ACTC, THEY ARE AS THE ARTICLE CLAIMS HAVING REGULAR ONE-ON-ONE MEETINGS WITH MANY OF THE BIGGEST PHARMACEUTICAL COMPANIES IN THE WORLD. ( Please see below )
Interview with Gary Rabin of Advanced Cell Technology (ACTC)
Posted on May 1, 2013 by admin
One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT).
At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS cell-related products such as platelets.
I interviewed ACT CEO and Chairman, Gary Rabin, to get the latest on the company and its future. I wanted to thank Gary and the other folks at ACT for doing this interview, which was an email Q&A. .
QUESTION: Any news on the partnership and/or JV front for ACT? Small partners??
We continue to have regular one-on-one meetings with many of the biggest pharmaceutical companies in the world. They are keenly interested in our programs, even beyond RPE. However, as we’ve said before, we want to make sure the timing of such a JV is appropriate and in the best long-terms interests of the company and its shareholders. The value of a deal halfway through phase I is likely to be significantly different than the value of a deal could command coming at the end of phase I, particularly with our ability to treat 8 “better vision” (20/100) patients in the second half of our trials.
( PART 2 ) Below part of the News release from ACTC May 16th 2013
We continue to be encouraged by the progress we see in our ongoing clinical investigations, though the results included in the article were confidential and not intended for publication at that time,” commented Gary Rabin, chairman and CEO of ACT. “Our plan is still to publish additional results from the clinical investigations when we have a significant aggregation of data.”
MY OPINION ONLY
How I read this ACTC did not want this News out at this time. They have this Patient that had 20/400 and now has 20/40 Vision, but what else is happening with other Patients and with the Company. I think They ACTC were hoping to package a HUGE news announcement with more News that what was disclosed prematurely.
I am a believer and am looking to add more shares.
Any guesses who maybe calling on ACTC. Again just guesses. I mean if they have, as they say, been having talks with big pharms. Now they have some Great and Exciting News. This story is just begging IN MY OPINION ONLY. Time keeps on ticking ticking into the future. The real Lyrics are Time keep's on slipping, slipping ,slipping, into the future, by Steve Miller.